NCT04679064 - Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | Biotech Hunter

Enrollment

427

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions

Ovarian Cancer

Interventions

DRUG

Niraparib

PARP-inihibitor

DRUG

Dostarlimab

PD-1 inihibitor

DRUG

Pegylated liposomal doxorubicin

Chemotherapy drug

DRUG

Paclitaxel

Chemotherapy drug

DRUG

Gemcitabine

Chemotherapy drug

DRUG

Topotecan

Chemotherapy drug

DRUG

Bevacizumab

Chemotherapy drug

Trial Locations (8)

Unknown

RECRUITING

Azienda Ospedaliera Spedali Civili, Brescia

RECRUITING

Istituto Tumori della Romagna IRST IRCCS, Meldola

RECRUITING

IEO-Istituto Europeo di Oncologia, Milan

RECRUITING

IRCCS Ospedale San Raffaele, Milan

RECRUITING

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples

RECRUITING

Nuovo Ospedale degli Infermi, Ponderano

RECRUITING

Istituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena, Rome

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome